The RTS,S/AS01 vaccine contains a recombinant form of CSP fused with a portion of the hepatitis B virus surface antigen. This fusion helps to enhance the immune response against CSP. When administered, the vaccine stimulates the immune system to produce antibodies and T cells that recognize and target the CSP, preventing the sporozoite from infecting the liver cells.
